Skip to main content
. Author manuscript; available in PMC: 2021 Sep 8.
Published in final edited form as: Vaccine. 2017 Feb 16;36(22):3090–3100. doi: 10.1016/j.vaccine.2017.01.068

Table II.

Passive transfer of immune serum or immune cells protects naïve BALB/c mice against lethal challenge.

group n treatment Survivors P value vs. control group
1 5 GP + CoVaccine HT™ (direct) 5/5 0.0040
2 5 VP24 + CoVaccine HT™ (direct) 2/5 >0.05
3 5 CoVaccine HT™ (direct) 0/5 Adjuvant control group
4 10 GP serum (1 ml)a 9/10 <0.0001
5 10 VP24 serum (1 ml)a 1/10 >0.05
6 10 Naïve 0/10 Challenge control group
7 10 GP T cells hi (1.5×10^7)b 7/10 p < 0.05f
8 10 VP24 T cells hi (1.5 ×10^7)b 8/10 p < 0.05f
9 10 GP T cells low (1.5×10^6)c 5/10 p < 0.05f
10 10 VP24 T cells low (1.5 ×10^6)c 5/10 p < 0.05f
11 10 GP+VP24 T cells hi (1.5 ×10^7 both)d 8/10 p < 0.05f
12 10 GP+VP24 T cells low (1.5×10^6 both)d 6/10 p < 0.05f
13 10 GP spleno hi (7×10^7)e 8/10 p < 0.05f
14 10 VP24 spleno hi (7 ×10^7)e 5/10 p < 0.05f
15 10 GP+VP24 spleno hi (7×10^7 both)e 8/10 p < 0.05f
a

1 ml of immune serum per mouse administered i.p.,

b

1.5×107 T-cells/mouse administered i.p.,

c

1.5×106 T-cells/mouse administered i.p,

d

mixed cells from group 1 (GP immunized) + group 2 (VP24 immunized) animals; indicated amount of cells administered from both groups into each animal,

e

Splenocyte (unfractionated) transfers: 7×107 cells/mouse,

f

Normal serum, T cell or splenocyte transfers were conducted in the past and have shown that the same amount of normal serum or number of normal T cells or splenocytes administered to mice yield 100% fatalities with the identical challenge virus and dose as administered in this experiment. Thus, all groups of mice receiving anti-GP serum or immune cells in this experiment had significant protection (p < 0.05) compared to mice receiving normal serum or cells.